Takeda Pharmaceutical and Enterome Bioscience have entered a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets, which would play crucial roles treating in gastrointestinal disorders.

Under the deal, Enterome will use its metagenomic platform to support the discovery of potential new small molecules or biologics agents from gut bacteria and directed to the GI targets selected by the companies.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Takeda will have an option to licence selected agents on an exclusive global basis and will be responsible for their regulatory and clinical development, as well as commercialisation.

"This strategic collaboration represents an important step towards unlocking the microbiome to generate new therapeutic solutions to serious diseases."

Enterome CEO Pierre Belichard said: "This strategic collaboration with Takeda is a significant achievement for Enterome and represents an important step towards realising the full potential of our expertise and unique capabilities in unlocking the microbiome to generate new therapeutic solutions to serious diseases.

"We are delighted to begin this new collaboration, which will combine our continuing leadership in the microbiome space and Takeda’s global therapeutic drug discovery and development capabilities.

"It is also an important step for Enterome towards achieving its ambition to become a leading global biopharmaceutical company in the microbiome space."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The deal will see Enterome receive an upfront payment and three-year R&D funding, and is eligible to receive additional payments in the form of option exercise, development, regulatory and commercial milestone payments for each molecule discovered through the collaboration.

In addition, Enterome is eligible to receive potential tiered royalties on the net sales of any products that are commercialised by Takeda.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact